GM3 Nanoparticles for Sustained Delivery of Anti-Retrovirals to Lymphatic Tissues
用于将抗逆转录病毒药物持续递送至淋巴组织的 GM3 纳米颗粒
基本信息
- 批准号:10056188
- 负责人:
- 金额:$ 62.6万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-11-08 至 2022-10-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAnti-Retroviral AgentsBindingCell membraneCell surfaceCellsClinical ResearchDataDendritic CellsDevelopmentDiseaseDrug toxicityEncapsulatedEnvironmentFutureGoalsHIVHIV-1HumanIn VitroIndividualInfectionInflammationLinkLymphaticLymphatic SystemLymphoid TissueMacacaMalignant NeoplasmsMembraneMembrane FluidityMetabolic DiseasesMusMyelogenousMyeloid CellsOralPenetrationPharmaceutical PreparationsPharmacodynamicsPlasmaPlayProcessPropertyRegulationResearchResearch PriorityResidual stateRoleSIVSecondary toSialic AcidsSiteSolidSpleenSubcutaneous InjectionsSurfaceTestingTherapeuticTimeTissuesTreatment EfficacyVaccine AntigenViralViral reservoirVirusVirus Replicationantiretroviral therapybasedesigndraining lymph nodeefficacy validationexosomeextracellularhumanized mouseimprovedin vivointravenous injectionlymph nodesmacrophagemouse modelnanonanoGoldnanocarriernanoparticlenanoparticle deliverynonhuman primatenovelnovel strategiespre-clinicalpreservationpreventsegregationsimian human immunodeficiency virussystemic toxicitytargeted deliverytraffickinguptakeviral reboundvirus development
项目摘要
PROJECT ABSTRACT
Despite widespread implementation of antiretroviral therapy (ART) that effectively suppresses virus replication
in the periphery, HIV persists in tissue reservoirs and accounts for the rapid plasma viral rebound in HIV-
infected individuals who have discontinued ART. It is well appreciated that secondary lymphoid tissues
represent a drug-privileged site that account for residual viral persistence in HIV-infected individuals on ART.
Hence, effective cure and eradication strategies require development of novel approaches that specifically
target lymph node-resident HIV reservoirs. An effective strategy to enhance anti-retroviral (ARV) drug
concentrations in secondary lymph nodes is to formulate ARVs in carriers such as nanoparticles that promote
transport of compounds via the lymphatics to the draining lymph nodes. Additionally, strategies that prevent
rapid clearance and maintain inhibitory concentrations of ARVs in lymph nodes for an extended time are
needed to effectively suppress persistent virus expression. Hence in this application, we are proposing to
develop GM3-containing membrane encapsulated nanoparticle-based approaches to establish long-term
tissue depots of ARVs in lymph nodes to suppress residual viral replication. The design of these nanoparticles
is based on our recent findings that demonstrate specific capture of GM3 (α2,3-linked sialic acid containing
monosialo-dihexosylganglioside) containing membrane encapsulated gold nanoparticles by CD169 expressing
primary human myeloid cells such as macrophages and dendritic cells in vitro and co-localization of GM3-gold
NPs with CD169+ cells in lymph nodes of mice. Interestingly, capture of GM3-gold NPs resulted in
sequestration and preservation within surface accessible non-lysosomal plasma membrane invaginations in
CD169+ myeloid cells. Hence, we will exploit these specific interactions between GM3-containing membrane
encapsulated nanoparticles and CD169 to achieve both selective targeting of lymph node resident-myeloid
cells and sequestration to specialized non-lysosomal compartments for formation of “drug depots” that achieve
sustained inhibitory concentrations of ARVs. Finally, we will determine the ability of these novel ARV-
containing nanocarriers to suppress virus replication in lymph nodes in a humanized mouse model of HIV-1
infection. We believe these studies are critical to development of virus-eradication strategies for eliminating
persistent HIV reservoir.
项目摘要
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SURYARAM GUMMULURU其他文献
SURYARAM GUMMULURU的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SURYARAM GUMMULURU', 18)}}的其他基金
Persistent HIV-1 expression and microglia dysfunction
HIV-1 持续表达和小胶质细胞功能障碍
- 批准号:
10624911 - 财政年份:2021
- 资助金额:
$ 62.6万 - 项目类别:
Persistent HIV-1 expression and microglia dysfunction
HIV-1 持续表达和小胶质细胞功能障碍
- 批准号:
10448401 - 财政年份:2021
- 资助金额:
$ 62.6万 - 项目类别:
Persistent HIV-1 expression and microglia dysfunction
HIV-1 持续表达和小胶质细胞功能障碍
- 批准号:
10327546 - 财政年份:2021
- 资助金额:
$ 62.6万 - 项目类别:
Persistent HIV expression induced type I IFN responses and inflammaging
持续的 HIV 表达诱导 I 型 IFN 反应和炎症
- 批准号:
10165448 - 财政年份:2018
- 资助金额:
$ 62.6万 - 项目类别:
Persistent HIV expression induced type I IFN responses and inflammaging
持续的 HIV 表达诱导 I 型 IFN 反应和炎症
- 批准号:
10396622 - 财政年份:2018
- 资助金额:
$ 62.6万 - 项目类别:
Persistent HIV expression induced type I IFN responses and inflammaging
持续的 HIV 表达诱导 I 型 IFN 反应和炎症
- 批准号:
9750592 - 财政年份:2018
- 资助金额:
$ 62.6万 - 项目类别:
Engineering a 3D human neurovascular unit for investigating and countering neuroinflammatory mechanisms of HIV
设计 3D 人类神经血管单元来研究和对抗 HIV 的神经炎症机制
- 批准号:
9502663 - 财政年份:2017
- 资助金额:
$ 62.6万 - 项目类别:
GM3 Nanoparticles for Sustained Delivery of Anti-Retrovirals to Lymphatic Tissues
用于将抗逆转录病毒药物持续递送至淋巴组织的 GM3 纳米颗粒
- 批准号:
10292451 - 财政年份:2017
- 资助金额:
$ 62.6万 - 项目类别:
Elucidating Non-Virus Encoded HIV Capture through Artificial Virus Nanoparticles
阐明通过人工病毒纳米颗粒捕获非病毒编码的 HIV
- 批准号:
8682127 - 财政年份:2013
- 资助金额:
$ 62.6万 - 项目类别:
GLYCOSPHINGOLIPID COMPOSITIONS DURING INFECTION BY HIV TYPE 1 (HIV-1) PARTICLES
HIV 1型(HIV-1)颗粒感染期间的糖鞘脂组合物
- 批准号:
8365588 - 财政年份:2011
- 资助金额:
$ 62.6万 - 项目类别:
相似海外基金
RESISTANCE OF HIV-1 TO ANTI-RETROVIRAL AGENTS
HIV-1 对抗逆转录病毒药物的耐药性
- 批准号:
3030975 - 财政年份:1993
- 资助金额:
$ 62.6万 - 项目类别:
POLYMERICS DELIVERY SYSTEMS FOR ANTI-RETROVIRAL AGENTS
抗逆转录病毒药物的聚合物递送系统
- 批准号:
3489187 - 财政年份:1990
- 资助金额:
$ 62.6万 - 项目类别:
DEVELOPMENTAL VIROLOGY RESEARCH--RESISTANCE TO ANTI-RETROVIRAL AGENTS
发育病毒学研究——抗逆转录病毒药物的耐药性
- 批准号:
2335293 - 财政年份:
- 资助金额:
$ 62.6万 - 项目类别:














{{item.name}}会员




